{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:27:33Z","timestamp":1792056453691,"version":"4.4.0"},"reference-count":108,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Thromboembolism in multiple myeloma (MM) patients remains a common complication that renders the optimization of our thromboprophylaxis practice necessary. This review aims to make clear the need for the development of more accurate risk assessment tools and means of thrombosis prevention. Current clinical practice is guided by available guidelines published by the IMWG in 2014, but the extent to which these are implemented is unclear. Recently, several groups developed clinical scores for thrombosis risk in MM in an attempt to improve risk stratification, but these have not been validated or used in clinical practice so far. Research in this field is increasingly focusing on understanding the unique coagulation profile of the MM patient, and data on potential biomarkers that accurately reflect hypercoagulability is emerging. Finally, promising evidence on the effectiveness of direct oral anticoagulants (DOACs) in the context of thrombosis prevention in MM patients is increasingly becoming available. The critical appraisal of the above research areas will establish the necessity of combining disease-specific clinical risk factors with coagulation biomarkers to allow more effective risk stratification that will eventually lead to the reduction of this significant complication. Results from ongoing clinical trials on the role of DOACs are much anticipated.<\/jats:p>","DOI":"10.3390\/cancers12010191","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:05:51Z","timestamp":1578888351000},"page":"191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools"],"prefix":"10.3390","volume":"12","author":[{"given":"Despina","family":"Fotiou","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1179\/102453312X13336169156933","article-title":"Thrombosis in multiple myeloma (MM)","volume":"17","author":"Braggio","year":"2012","journal-title":"Hematology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0034-1370793","article-title":"Venous thromboembolism in multiple myeloma","volume":"40","author":"Za","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","article-title":"Thrombosis in multiple myeloma","volume":"2010","author":"Kristinsson","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1160\/TH13-02-0140","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Schoen, M.W., Luo, S., Gage, B., Carson, K.R., and Sanfilippo, K.M. (2018). Association of venous thromboembolism with increased mortality in patients with multiple myeloma. J. Clin. Oncol.","DOI":"10.1200\/JCO.2018.36.15_suppl.8051"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CEOR.S39964","article-title":"Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States","volume":"5","author":"Khorana","year":"2013","journal-title":"Clin. Outcomes Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2009.22.3958","article-title":"Anticoagulation in the treatment of established venous thromboembolism in patients with cancer","volume":"27","author":"Lee","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and Cost of Myeloma Therapy","volume":"38","author":"Rajkumar","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/MBC.0000000000000296","article-title":"Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma","volume":"26","author":"Huang","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-131691","article-title":"Hyperviscosity in plasma cell dyscrasias","volume":"55","author":"Kwaan","year":"2013","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","article-title":"Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement","volume":"25","author":"Dimopoulos","year":"2011","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/17474086.2016.1194750","article-title":"A review of the venous thrombotic issues associated with multiple myeloma","volume":"9","author":"Fotiou","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_21","unstructured":"(2019, December 12). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Cancer-Associated Venous Thromboembolic Disease. Available online: www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Baker, H.A., Brown, A.R., Mahnken, J.D., Shireman, T.I., Webb, C.E., and Lipe, B.C. (2018). Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. Cancer Med.","DOI":"10.1002\/cam4.1927"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood-2017-05-782961","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma","volume":"130","author":"Paludo","year":"2017","journal-title":"Blood"},{"key":"ref_24","first-page":"553","article-title":"Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study","volume":"130","author":"Bradbury","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"Ay","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brown, J.D., and Adams, V.R. (2016). Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. Healthcare, 4.","DOI":"10.3390\/healthcare4010016"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ajh.23504","article-title":"Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens","volume":"88","author":"Bagratuni","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: Limited effectiveness of thromboprophylaxis","volume":"118","author":"Anaissie","year":"2012","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/rth2.12161","article-title":"Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study","volume":"3","author":"Chalayer","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_31","first-page":"1141","article-title":"Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma","volume":"89","author":"Galli","year":"2004","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","article-title":"Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study","volume":"129","author":"Cortelezzi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CLM.2003.n.011","article-title":"Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival","volume":"4","author":"Zangari","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1160\/TH10-03-0187","article-title":"Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma","volume":"105","author":"Auwerda","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MBC.0000000000000315","article-title":"Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: Association with thromboembolic complications","volume":"26","author":"Undas","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1007\/s12032-012-0290-0","article-title":"Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma","volume":"29","author":"Robak","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(96)90116-X","article-title":"Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma","volume":"128","author":"Carr","year":"1996","journal-title":"J. Lab. Clin. Med."},{"key":"ref_38","first-page":"H1195","article-title":"Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma","volume":"266","author":"Carr","year":"1994","journal-title":"Am. J. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0031-1273085","article-title":"Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis","volume":"37","author":"Zamagni","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2042098612452291","article-title":"Venous and arterial thrombotic risks with thalidomide: Evidence and practical guidance","volume":"3","author":"Palumbo","year":"2012","journal-title":"Adv. Drug Saf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1096-8652(199604)51:4<319::AID-AJH12>3.0.CO;2-9","article-title":"Acquired free protein S deficiency associated with multiple myeloma: A case report","volume":"51","author":"Deitcher","year":"1996","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0049-3848(86)90221-5","article-title":"Functional deficiency of protein C and skin necrosis in multiple myeloma","volume":"42","author":"Gruber","year":"1986","journal-title":"Thromb. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1096-8652(199910)62:2<99::AID-AJH6>3.0.CO;2-N","article-title":"Light-chain paraproteins with lupus anticoagulant activity","volume":"62","author":"Yasin","year":"1999","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2017.03.010","article-title":"Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients","volume":"65","author":"Leiba","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Dargaud, Y., Fouassier, M., Bordet, J.C., Ducastelle-Lepretre, S., Dumontet, C., Moreau, P., and Michallet, M. (2019). The challenge of myeloma-related thromboembolic disease: Can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?. Leuk. Lymphoma, 1\u20134.","DOI":"10.1080\/10428194.2019.1585839"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2010.01434.x","article-title":"Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: Thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin","volume":"84","author":"Cini","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"Auwerda","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/17474086.2019.1604214","article-title":"Updates on thrombotic events associated with multiple myeloma","volume":"12","author":"Fotiou","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00001721-200203000-00005","article-title":"Cytokines in coagulation and thrombosis: A preclinical and clinical review","volume":"13","author":"Joseph","year":"2002","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JBM.S147743","article-title":"Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma","volume":"9","author":"Nomura","year":"2018","journal-title":"J. Blood Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.thromres.2007.05.016","article-title":"In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide","volume":"121","author":"Petropoulou","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1076029615625825","article-title":"Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance","volume":"22","author":"Crowley","year":"2016","journal-title":"Clin. Appl. Thromb. Hemost"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/10428194.2016.1219900","article-title":"Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma","volume":"58","author":"Tiong","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2017.08.011","article-title":"Hypocoagulability as assessed by thrombin generation test in newly-diagnosed patients with multiple myeloma","volume":"66","author":"Legendre","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-018-0135-y","article-title":"Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: Results of the prospective ROADMAP-MM-CAT study","volume":"8","author":"Fotiou","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1002\/cncr.28274","article-title":"Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma","volume":"119","author":"Fouquet","year":"2013","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bjh.12152","article-title":"Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: An observational study","volume":"160","author":"Rosovsky","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: A randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1038\/bcj.2014.77","article-title":"Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"4","author":"Dimopoulos","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-014-0196-6","article-title":"Pomalidomide: A review of its use in patients with recurrent multiple myeloma","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","article-title":"Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: Review of data from phase 3 trials and studies of novel combination regimens","volume":"11","author":"Zangari","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","article-title":"Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study","volume":"11","author":"Dimopoulos","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_75","first-page":"15","article-title":"Profile of elotuzumab and its potential in the treatment of multiple myeloma","volume":"2014","author":"Liu","year":"2014","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.thromres.2014.05.032","article-title":"Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma","volume":"134","author":"Gil","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/MBC.0b013e3283642ee2","article-title":"Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin","volume":"24","author":"Abdullah","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1160\/TH04-10-0652","article-title":"High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men","volume":"94","author":"Jilma","year":"2005","journal-title":"Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1538-7836.2009.03300.x","article-title":"Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes","volume":"7","author":"Swystun","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thromres.2007.06.013","article-title":"Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro","volume":"121","author":"Avcu","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sanfilippo, K.M., Wang, T.F., Luo, S., Thomas, T.S., Carson, K.R., Keller, J.W., Kuderer, N.M., Calverley, D., and Gage, B. (2018). Predictive ability of the khorana score for venous thromboembolism (VTE) in multiple myeloma (MM). J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.15_suppl.e18733"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1634\/theoncologist.2017-0530","article-title":"Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-associated Thrombosis. The Observational ROADMAP-CAT Study","volume":"23","author":"Syrigos","year":"2018","journal-title":"Oncol. Press."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Sanfilippo, K.M., Luo, S., Wang, T.F., Fiala, M., Schoen, M., Wildes, T.M., Mikhael, J., Kuderer, N.M., Calverley, D.C., and Keller, J. (2019). Predicting venous thromboembolism in multiple myeloma: Development and validation of the IMPEDE VTE score. Am. J. Hematol.","DOI":"10.1002\/ajh.25603"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide\u2014A systematic review","volume":"141","author":"Bermejo","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma\u2014Choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_92","first-page":"3419","article-title":"Aspirin May be Inadequate Thromboprophylaxis in Multiple Myeloma","volume":"130","author":"Sanfilipo","year":"2017","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11239-017-1534-9","article-title":"Use of direct oral anticoagulants in patients on immunomodulatory agents","volume":"44","author":"Man","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Storrar, N.P.F., Mathur, A., Johnson, P.R.E., and Roddie, P.H. (2018). Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br. J. Haematol.","DOI":"10.1111\/bjh.15392"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fonc.2019.00045","article-title":"Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy","volume":"9","author":"Cornell","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2018.09.015","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions","volume":"132","author":"Riess","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.06.015","article-title":"Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences","volume":"129","author":"Bellesoeur","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Frere, C., Benzidia, I., Marjanovic, Z., and Farge, D. (2019). Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. Cancers, 11.","DOI":"10.3390\/cancers11010071"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2019.02.031","article-title":"Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants","volume":"177","author":"Vedovati","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2016.06.011","article-title":"Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: Report of 5 cases and literature review","volume":"105","author":"Lim","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia","volume":"91","author":"Khanal","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_106","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus","volume":"17","author":"Napolitano","year":"2018","journal-title":"Blood Transfus."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., and Marquis, K. (2018). Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1814468"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2018-99-111897","article-title":"Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism","volume":"132","author":"Park","year":"2018","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/1\/191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:05:02Z","timestamp":1760364302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/1\/191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["cancers12010191"],"URL":"https:\/\/doi.org\/10.3390\/cancers12010191","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}